ETHZilla Corporation Warrant (ATNFW)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
ETHZilla Corporation Warrant (ATNFW) with AI Score 46/100 (Weak). ETHZilla Corporation Warrant (ATNFW) is associated with 180 Life Sciences Corp. , a clinical-stage biotechnology company. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 18, 2026ETHZilla Corporation Warrant (ATNFW) Healthcare & Pipeline Overview
ETHZilla Corporation Warrant is linked to 180 Life Sciences Corp., a clinical-stage biotech firm targeting inflammatory diseases, fibrosis, and pain. Founded in 2016, the company leverages expertise from leading universities to develop novel therapeutics, operating within the competitive pharmaceutical sector.
Investment Thesis
An investment in ETHZilla Corporation Warrant reflects the potential of 180 Life Sciences Corp.'s clinical-stage pipeline targeting inflammatory diseases, fibrosis, and pain. The company's approach of leveraging expertise from top universities provides a scientific foundation for its drug development programs. Key value drivers include successful clinical trial outcomes, regulatory approvals, and strategic partnerships. The company's small market capitalization and limited employee count (4) indicate a high-risk, high-reward profile. Investors should closely monitor clinical trial progress and regulatory milestones to assess the potential for long-term value creation. The beta of 0.41 suggests lower volatility compared to the overall market.
Based on FMP financials and quantitative analysis
Key Highlights
- 180 Life Sciences Corp. focuses on developing drugs for inflammatory diseases, fibrosis, and pain.
- The company was founded in 2016 by Marc Feldmann, Lawrence J. Steinman, and Jonathan B. Rothbard.
- Headquartered in Palo Alto, CA, 180 Life Sciences leverages expertise from Oxford University, the Hebrew University, and Stanford University.
- The company operates as a clinical-stage biotechnology company.
- The company's market cap is $0.00B, indicating a micro-cap status.
Competitors & Peers
Strengths
- Expertise in inflammatory diseases, fibrosis, and pain.
- Collaborations with leading universities.
- Proprietary drug candidates.
- Focus on unmet medical needs.
Weaknesses
- Clinical-stage company with no approved products.
- Limited financial resources.
- Small employee count.
- Dependence on clinical trial outcomes.
Catalysts
- Upcoming: Clinical trial results for lead drug candidates.
- Upcoming: Regulatory submissions for potential drug approvals.
- Ongoing: Progress in research and development programs.
- Ongoing: Strategic partnerships and collaborations.
Risks
- Potential: Clinical trial failures.
- Potential: Regulatory delays or rejections.
- Potential: Competition from other pharmaceutical companies.
- Ongoing: Dependence on securing additional funding.
- Ongoing: Patent litigation or challenges to intellectual property.
Growth Opportunities
- Expansion into New Therapeutic Areas: 180 Life Sciences can expand its focus to include additional inflammatory and fibrotic diseases beyond its current pipeline. The market for autoimmune and inflammatory disease treatments is projected to reach $150 billion by 2028, presenting a significant growth opportunity. Successful development and commercialization of new therapies in these areas could drive substantial revenue growth for the company.
- Strategic Partnerships and Collaborations: Partnering with larger pharmaceutical companies or research institutions can provide 180 Life Sciences with access to additional resources, expertise, and funding. Collaborative agreements can accelerate drug development timelines, expand market reach, and reduce financial risk. The company can pursue partnerships for specific drug candidates or platform technologies.
- Advancements in Drug Delivery Technologies: Utilizing innovative drug delivery systems, such as targeted nanoparticles or sustained-release formulations, can improve the efficacy and safety of 180 Life Sciences' drug candidates. These technologies can enhance drug bioavailability, reduce side effects, and improve patient compliance. Investing in drug delivery research and development can provide a competitive advantage.
- Geographic Expansion: Expanding into new geographic markets, particularly in Asia and Europe, can increase the potential patient population for 180 Life Sciences' therapies. These regions have growing healthcare markets and increasing demand for innovative treatments. Establishing a presence in these markets through partnerships or direct operations can drive revenue growth and diversify the company's revenue streams.
- Orphan Drug Designations: Pursuing orphan drug designations for its therapies can provide 180 Life Sciences with market exclusivity, tax incentives, and expedited regulatory review. Orphan drug designations are granted to therapies targeting rare diseases or conditions affecting fewer than 200,000 people in the United States. This strategy can enhance the commercial attractiveness of the company's drug candidates.
Opportunities
- Expansion into new therapeutic areas.
- Strategic partnerships and collaborations.
- Advancements in drug delivery technologies.
- Geographic expansion.
Threats
- Clinical trial failures.
- Regulatory hurdles.
- Competition from established pharmaceutical companies.
- Patent expirations.
Competitive Advantages
- Proprietary drug candidates with patent protection.
- Expertise in inflammatory diseases, fibrosis, and pain.
- Collaborations with leading universities.
- Established clinical trial infrastructure.
About ATNFW
180 Life Sciences Corp., associated with ETHZilla Corporation Warrant (ATNFW), is a clinical-stage biotechnology company established on September 7, 2016, by Marc Feldmann, Lawrence J. Steinman, and Jonathan B. Rothbard. Headquartered in Palo Alto, CA, the company focuses on developing innovative drugs to address unmet medical needs in inflammatory diseases, fibrosis, and pain management. The company leverages the combined expertise of researchers from Oxford University, the Hebrew University, and Stanford University to advance its therapeutic programs. 180 Life Sciences is dedicated to translating cutting-edge research into effective treatments for conditions with limited therapeutic options. Their approach involves identifying and validating novel targets, developing proprietary drug candidates, and conducting rigorous clinical trials to demonstrate safety and efficacy. The company's pipeline includes programs targeting various inflammatory and fibrotic diseases, as well as chronic pain conditions. By focusing on areas with significant unmet needs, 180 Life Sciences aims to improve the lives of patients suffering from these debilitating conditions.
What They Do
- Develops novel drugs for inflammatory diseases.
- Creates therapies for fibrosis.
- Researches treatments for chronic pain.
- Leverages expertise from Oxford University, the Hebrew University, and Stanford University.
- Conducts clinical trials to evaluate drug safety and efficacy.
- Identifies and validates novel drug targets.
Business Model
- Develops and patents novel drug candidates.
- Conducts preclinical and clinical research to demonstrate safety and efficacy.
- Seeks regulatory approval from agencies like the FDA.
- Out-licenses or commercializes approved drugs.
Industry Context
180 Life Sciences Corp. operates within the competitive medical-pharmaceuticals industry. This sector is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition from established pharmaceutical companies and other biotechnology firms. Market trends include a growing demand for novel therapies targeting chronic diseases, advancements in drug delivery technologies, and increasing regulatory scrutiny. The company's success depends on its ability to successfully navigate these challenges and bring its drug candidates to market.
Key Customers
- Patients suffering from inflammatory diseases.
- Patients with fibrotic conditions.
- Individuals experiencing chronic pain.
- Healthcare providers prescribing treatments.
Financials
Chart & Info
ETHZilla Corporation Warrant (ATNFW) stock price: Price data unavailable
Latest News
No recent news available for ATNFW.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ATNFW.
Price Targets
Wall Street price target analysis for ATNFW.
MoonshotScore
What does this score mean?
The MoonshotScore rates ATNFW's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Leadership: Lloyd Blair Jordan
Unknown
Information on Lloyd Blair Jordan's background is not available in the provided data. Without additional context, it's challenging to provide a comprehensive biography. Further research would be needed to determine his career history, educational background, and previous roles before managing 180 Life Sciences Corp.
Track Record: Information on Lloyd Blair Jordan's track record is not available in the provided data. It is unknown what key achievements, strategic decisions, or company milestones have occurred under his leadership. Further research would be needed to assess his performance and contributions to the company.
Common Questions About ATNFW
What does ETHZilla Corporation Warrant do?
ETHZilla Corporation Warrant is associated with 180 Life Sciences Corp., a clinical-stage biotechnology company focused on developing novel drugs for inflammatory diseases, fibrosis, and pain. The company leverages expertise from leading universities to identify and validate drug targets, conduct clinical trials, and seek regulatory approvals. Their business model involves developing and patenting drug candidates, conducting research, and out-licensing or commercializing approved therapies. The company aims to address unmet medical needs in areas with limited treatment options.
What do analysts say about ATNFW stock?
AI analysis is currently pending for ATNFW. Without analyst ratings or price targets, it is difficult to provide a consensus view on the stock's potential. Investors should conduct their own due diligence and consider factors such as clinical trial progress, regulatory milestones, and financial performance. The company's small market capitalization and clinical-stage nature indicate a higher-risk investment profile. Monitor company announcements and industry developments for updates.
What are the main risks for ATNFW?
The primary risks for ETHZilla Corporation Warrant, linked to 180 Life Sciences Corp., include clinical trial failures, regulatory hurdles, and competition from established pharmaceutical companies. Clinical trial failures can significantly impact the company's pipeline and valuation. Regulatory delays or rejections can delay or prevent drug approvals. Competition from larger companies with greater resources can limit market share. Additionally, the company faces risks related to securing additional funding and protecting its intellectual property.
What are the key factors to evaluate for ATNFW?
ETHZilla Corporation Warrant (ATNFW) currently holds an AI score of 46/100, indicating low score. Key strength: Expertise in inflammatory diseases, fibrosis, and pain.. Primary risk to monitor: Potential: Clinical trial failures.. This is not financial advice.
How frequently does ATNFW data refresh on this page?
ATNFW prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven ATNFW's recent stock price performance?
Recent price movement in ETHZilla Corporation Warrant (ATNFW) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Expertise in inflammatory diseases, fibrosis, and pain.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider ATNFW overvalued or undervalued right now?
Determining whether ETHZilla Corporation Warrant (ATNFW) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying ATNFW?
Before investing in ETHZilla Corporation Warrant (ATNFW), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited financial data available.
- AI analysis pending.
- Information based on available sources as of 2026-03-18.